Zentalis Pharmaceuticals (ZNTL) Competitors $1.45 +0.07 (+5.07%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 08/7/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. VIGL, AQST, ETON, ATXS, FULC, PRTA, OLMA, CYRX, CAPR, and HUMAShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Vigil Neuroscience (VIGL), Aquestive Therapeutics (AQST), Eton Pharmaceuticals (ETON), Astria Therapeutics (ATXS), Fulcrum Therapeutics (FULC), Prothena (PRTA), Olema Pharmaceuticals (OLMA), CryoPort (CYRX), Capricor Therapeutics (CAPR), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Its Competitors Vigil Neuroscience Aquestive Therapeutics Eton Pharmaceuticals Astria Therapeutics Fulcrum Therapeutics Prothena Olema Pharmaceuticals CryoPort Capricor Therapeutics Humacyte Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Which has more risk & volatility, ZNTL or VIGL? Zentalis Pharmaceuticals has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.33, meaning that its share price is 233% more volatile than the S&P 500. Do institutionals & insiders hold more shares of ZNTL or VIGL? 83.6% of Vigil Neuroscience shares are held by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 18.0% of Vigil Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, ZNTL or VIGL? Vigil Neuroscience has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Vigil Neuroscience is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$67.43M1.55-$165.84M-$2.26-0.64Vigil NeuroscienceN/AN/A-$84.26M-$2.05-3.93 Does the media refer more to ZNTL or VIGL? In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Vigil Neuroscience. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 5 mentions for Vigil Neuroscience. Zentalis Pharmaceuticals' average media sentiment score of 1.08 beat Vigil Neuroscience's score of -0.14 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vigil Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ZNTL or VIGL? Zentalis Pharmaceuticals currently has a consensus target price of $8.20, suggesting a potential upside of 465.52%. Vigil Neuroscience has a consensus target price of $10.80, suggesting a potential upside of 34.16%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Vigil Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Vigil Neuroscience 0 Sell rating(s) 10 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ZNTL or VIGL more profitable? Zentalis Pharmaceuticals' return on equity of -49.48% beat Vigil Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -49.48% -38.60% Vigil Neuroscience N/A -111.70%-74.67% SummaryZentalis Pharmaceuticals beats Vigil Neuroscience on 9 of the 14 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.29M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-0.6417.9729.9425.14Price / Sales1.55262.51398.9486.71Price / CashN/A41.8335.9458.58Price / Book0.317.238.105.59Net Income-$165.84M-$54.43M$3.26B$265.48M7 Day Performance8.21%0.22%0.68%1.22%1 Month Performance14.17%5.59%2.46%0.39%1 Year Performance-56.19%9.98%27.69%23.47% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals2.4424 of 5 stars$1.45+5.1%$8.20+465.5%-55.8%$99.29M$67.43M-0.64160News CoveragePositive NewsEarnings ReportAnalyst ForecastHigh Trading VolumeVIGLVigil Neuroscience3.1212 of 5 stars$8.05flat$10.80+34.2%N/A$383.88MN/A0.0040Upcoming EarningsHigh Trading VolumeAQSTAquestive Therapeutics1.6844 of 5 stars$4.02+5.2%$10.14+152.3%+14.6%$379.43M$57.56M-6.81160ETONEton Pharmaceuticals2.0425 of 5 stars$14.39+1.8%$29.67+106.2%+337.2%$378.93M$39.01M-79.9420News CoverageEarnings ReportATXSAstria Therapeutics2.1882 of 5 stars$6.89+5.0%$29.00+320.9%-30.9%$370.21MN/A-3.6830Positive NewsUpcoming EarningsFULCFulcrum Therapeutics2.4498 of 5 stars$6.96+1.9%$7.57+8.8%-17.9%$369.45M$80M-5.70100PRTAProthena2.9403 of 5 stars$6.94+1.9%$31.50+353.9%-59.9%$366.56M$135.16M-3.34130News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.0997 of 5 stars$5.41+1.5%$24.50+352.9%-62.4%$364.68MN/A-2.6970CYRXCryoPort3.6576 of 5 stars$7.16-1.5%$10.63+48.4%+5.5%$364.50M$228.38M-3.061,186Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionGap UpCAPRCapricor Therapeutics3.5897 of 5 stars$7.68-2.8%$22.56+193.7%+126.7%$360.85M$22.27M-5.41101Trending NewsHUMAHumacyte1.8981 of 5 stars$2.26-0.9%$11.71+418.3%-68.5%$353.67M$1.57M0.00150Upcoming Earnings Related Companies and Tools Related Companies VIGL Competitors AQST Competitors ETON Competitors ATXS Competitors FULC Competitors PRTA Competitors OLMA Competitors CYRX Competitors CAPR Competitors HUMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZNTL Stock Alerts